Clinical Trial

Cross-over Study of Coronary Risk Factors With a Polypill

Study acronym: POLICROSS
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-08-30; most recent amendment 2025-08-04.
Status change: Not Yet Recruiting → Recruiting 2022-11-16
Trial Details
NCT Number NCT05030818
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease
Enrollment 88 participants
Start Date 2022-10-14
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-05